We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Plethora | LSE:PLE | London | Ordinary Share | GB00B06GL868 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.375 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/3/2015 17:17 | Jim Mellon on twitter, "anyone worried about the completely irrational fall in PLE shareprice this afternoon can meet Jamie Gibson at the Master Invstr April 25th" | adred | |
30/3/2015 16:38 | It is the product and competition also method of useage - sorry I cannot be explicit here as a public BB and the hounds of the PC police would be after me but I am sure readers can imagine !!!!!!! - not of course helped by management - or lack of it. Good luck to all who still hold - | pugugly | |
30/3/2015 16:35 | The smart people sold in November 13 | greenrookie | |
30/3/2015 16:21 | Anybody who bothered to read the previous announcements would have known about the 2p debt conversion. Most of Maven's prior holding was converted and the stock sold last year (That was largely what depressed the price). The majority of the remainder is held by Jim Mellon and he certainly is not a seller. Shareholders should also have known all about the change in number of dosages in the canister and the fact that the company has had to go back to the EMA for approval. The smart people will be buying now. | wiseacre | |
30/3/2015 15:46 | Perhaps the BOD will decide later a 10 dose one is the answer free stock charts from uk.advfn.com | buywell2 | |
30/3/2015 15:44 | I'd have thought a 20 dose can would be more cost effective than the 6 dose one in terms of packaging. Does the fact it cost more up front matter if the full 20 doses get used before the expiry ? The 6 dose can is more to do with maximising profit than the 20 dose. | al h | |
30/3/2015 15:41 | 20 is a hard sell hence why the 6 dose was required | adred | |
30/3/2015 15:40 | Jim tweeted this earlier knowing what was about to come out from PLE:@jimmhk: The reason I don't play with fire in chat room favourites is best illustrated by Quindell today. Up 25 pc. Bears are being fully roasted.If QPP shorters have been roasted then how would he describe what's happened to us? | richf75 | |
30/3/2015 15:36 | I wouldn't say Mellon is solely responsible, but the 20 dose can whiffs of greed. They'll still launch the 20 in EU with a 6 to follow. But how the cost of 20 is greeted by the Dr's etc will hinder sales. That must be a given, else why the 6 dose. | boysie72 | |
30/3/2015 15:27 | Jim Mellon has lost all credibility here. | bobby.ifa | |
30/3/2015 15:13 | Too risky to trade even at this level imo - I have never been anything other than underwhelmed by the management here. WG | weegeordie | |
30/3/2015 15:04 | Another cash call looming. That's something you can be certain of in companies with little revenue and very high expenditure and costs. | nick rubens | |
30/3/2015 15:03 | this dung going sub 2p today most probably | bad robot | |
30/3/2015 14:58 | You are right AL H that we knew about the remaining chunk of 2p shares ; of course we did not know about the issues with the 6 dose cannister. I am assuming that they will not complete the discussions with the 2 pharma companies until they get EMA approval for the 6 dose cannister. I have read the going concern statement carefully. They could be in a cash bind; as they say they will need $5m for the US marketing and their R & D costs are going up;£1.7m in the second half of last year alone.In addition corporate expenses of £1m each 6 months.They are thus dependent on the EMA approval to trigger the E6m from Recordati. For me not worth selling at under 4p a share but will need to think before buying more. | cerrito | |
30/3/2015 14:51 | Could get nasty if share price falls below 2p before 31/03/15. Note holders would then not convert into shares and demand repayment in cash!! | henley2 | |
30/3/2015 14:42 | Sold out today :-( Lost faith in the company now. | adred | |
30/3/2015 14:32 | If you can end up buying between 1.5 to 2p, then it's a bargain. Mind boggling these were low 20's with the hype. Still, they have a valid and required product. Wonder what Mellons take on it is! | boysie72 | |
30/3/2015 14:28 | So that we be about 400 million new shares at 2p then. Currently only about 600million in issue. Massive dilution and extended timescales. Not happy :-(( | tomthedom | |
30/3/2015 14:28 | Run for the exit; run for your lives!!! | greenrookie |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions